Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you agree to 2-3 or less you are contributing to my main point, thank you!
Again thank you for contributing even if only 1 year of runway! The less we have the more you are contributing to my class action point!
Thank you
No you are missing the class action part if the claims, they are still sticking to are not true, which would be detrimental to the share price and ability to raise money for these new trials in our pipeline.
We have approximately 4-5 year of runway cash.
It would also jeopardize Rett commercialisation and leave us open. To low ball offers from potential partnership
Assuming Excellence has great results.
PD and the supposed P3 PM .
So an if an investor truly believed the above should they not wait for the news of P3 PM and consequences before getting in?
Odd no?
Risk p3 PM and lawsuits rewards AA.
By the odds you gave previously its odd to me. Pun intended.
You know who is also pretty good at reading data and stats?
Dr.Jin and he has more data than you available to him.
Imagine that!
So this Investor should still feel comfortable investing in a company that claimed to have met all endpoints in AD and has not retracted that statement leaving them open to class action?
Have you gotten a response on this from one of the top echelon of Biotechnology investors?
They usually get much respect and call back from IR with very good information
Just stating that If Anavex Indeed did not meet end points then the legal actions would not be worth the while for me.
Then why stay invested if drawing such conclusions, an investor may ask himself.
Not what I was asking links to you about.
But hey thanks for those links, they seem to satisfy others.
I doubt Jin doesnt or didnt have other offers of employment.
I wonder why he chose us?
I was not asking for links about Dr.Jin as an FDA stat guy.
I was asking for links about those companies claimed to have met all AD endpoints and later retracted that claim due to lawsutis, also in which an FDA statistician joined after seeing their data after these claims.
Context matters, no matter how many links are provided, they are useless if they dont back up the claim in context.
Confirmation bias cuts both ways lol
No for me to throw one back for obvious reasons!
Enjoy the new bike!
Is all I can say, hopefully next run up you won't be riding it without shares.
GL!
Envy is not my goal, each investor has the power to choose.
My belive is not blind, is based on what we know to date.
7 years and counting of seeing what is occurring in this company.
I encourage others to do their own judging.
I seriously doubt the top FDA Stat guy has to wait 3-6 month to land a BP job or in another bio.
Playing devil advocate too.
Cool link
Yea well this Investor enjoyed the ride up to 30 while others were enjoying a motorcycle ride.
Now I have the luxury to not worry about 1-3 dollar moves.
Specially since they are non related to AVXL.
I call this an oprtunity to reload on the cheap.
Yea sure there are, not denying that.
I just haven't seen any that have claimed what we have in AD meeting all endpoints.
Then hiring an FDA guy and him accepting and staying even after seeing the data.
Have you? Any links?
I do what I do. Bullshit detector hasn't gone off on Anavex.
Not an expert, just a person with some logic and guts.
An electrical engineer and software developer, not an expert there either.
Just constantly learning.
But I do consider myself an expert at human behavior and bullshit detection.
Life university has taught me well, and validated me.
Respectfully save the words, bring the action.
The Doc will speak when is time to speak, in other words when we have data to discuss.
Anything else is a pump, which will be followed by a dump.
For now, is this not a TRADERS dreamland?
Market volatility exclaims so.
Yes the change of context is the message.
I know what to do when I feel the way you claim.
What I am saying is that I do my looking though my own eyes.
I dont care the CEO or current share price for that matter.
I care about the potentiality of the compound being approved based on data I care about.
Which is ZERO debt, money in the bank, and results thus far indicating a high chance of approval in MULTIPLE indications.
Again to each their own...
All I can do is laugh.
Not for the reasonable.
I would never be invested if I had the slightest though of dealing with a Madoff character.
Not even if I had free riding shared.
But go figure, different strokes for different folks.
Very nice sample of 2!
Except dizziness can be mitigate by dosage timing.
Oops!
They have market exclusivity from approval date on.
I agree I have sold for a loss many stocks that I stopped believing on for numerous reasons.
Since I sold for a loss, all I got was the lessons, which are pretty valuable to me.
I never ever ever held and complaint every single day!
I doesnt make logical sense to me.
I agree and we shall see, as investor I says.
Great thing is that "The Market" is clearly wrong about many things, just look at the MACRO environment and how over leveraged it is due to its free money (via rates) addiction.
The Market, is in deep schiiiett, so I dont trust their assessment of AVXL at all!!
No thanks!
True backer here which disagrees, remember the wanting of interim peek?
What a horrible approach that would have been for AVXL....
I agree, Jones.
I dont understand the FUD logic of hiring someone 3-4 years before hand.
Dr.M is no financial idiot, as he has shown a savvy businessman!
Do not believe the PM 3-4 years spin.
We already have what is considered to be PM trials in today's environment with our genomic subgrouping analysis with the KEM tool, and surrogate points.
The ones that do not believe we are conducting PM trials is because they are using THEIR own interpretation of the guidance in order to SPIN I suspect.
I guess rolling too many balls up a hill may result in some balls hitting the face.
That is just my guess, some want precisely this, especially the short cabal!
No, I recommend that FUDSTERS keep their eyes on the ball!
Which is RETT and AD for now!
Other trials are initiating in PD as we investors have learned from Australian news!
In the real world if you got 2 indications in the verge of approval, you focus on those.
But hey only in the real world.
Two different MOA, that hopefully do not interfere with each other.
In terms of price, well is up to the programs that pay for these drugs to do the cost/benefit analysis of single vs combo to patients impact.
These programs may potentially force ACAD, to lower their price making the combo treatment more affordable to them.
We dont know AVXL pricing yet, but assuming 300k, ACAD can potentially lower theirs to meet us there (300k), at a total of 600K a year for the combo.
Remember these patients dont pay out of pocket, unless they are very wealthy. ACAD rather something than nothing.
The program can say, sorry either lower, or we only cover 2-73 at the lower price tag.
I dont believe it will be a single treatment, it might be a combination of both drugs.
Also, if our drug happens to help the micro biota in the gut, in a positive way, allowing a more diverse growth of good bacteria.
We might even help with their side effects, of the schiiietts.
The relationship might be the other way around, and this might not do anything to help the gut.
In other words, healthy gut (diverse micro biota with good bacteria) is what allows proper absorption and concentration, in order to achieve therapeutic levels.
AD data and PDD OLE data will help clarify the relationship.
History has taught us that being first to market is not always best.
Being second to market with a drug that doesnt have the side effects of the first, of diarrhea in a disease that is so physically debilitating, is.
What they did set for us is as you mentioned is a very high price tag.
Imagine we come in and price our drug at 300K a year (to match Steady`s estimates), with less side effect, and hopefully more efficacy, worst case same efficacy.
In worst case scenario, that there is no combo treatment which is suspect there will be, who would insurance rather cover?
Or rather what would be cheaper for the special programs in place which cover these treatments?
Asking for a friend in Care Bear Land, aka Denmark.